Health
Hims & Hers Acquires Trybe Labs, Boosting At-Home Lab Testing Services

NEW YORK, NY — Hims & Hers Health announced Wednesday its acquisition of Trybe Labs, an at-home lab testing facility based in New Jersey. This strategic move is expected to enhance the telehealth company’s offerings by providing comprehensive pretreatment testing solutions to users.
“Access to richer data allows us to deepen the insights that providers can use on our platform to guide their clinical decisions for each individual patient,” said Dr. Patrick Carroll, chief medical officer of Hims & Hers. He emphasized that this acquisition represents a significant step toward elevating personal healthcare expectations.
The company did not disclose the financial terms of the deal but confirmed that it was funded through available cash resources. The rollout of new testing options is anticipated to occur over the next year, with pricing details to be shared upon availability.
This acquisition positions Hims & Hers to compete with established blood-drawing services like Labcorp and Quest Diagnostics. The company has ambitious plans to expand its services just months after entering the weight loss drug market.
Dr. Carroll criticized traditional pharmaceutical pricing, stating, “The healthcare that customers expect and deserve today is on-demand care with treatments designed specifically for them.” While Hims & Hers shares have experienced volatility, they have exhibited a positive trend, soaring 141% year-to-date as of Tuesday’s close.
The news of the acquisition sent shares up by more than 20% in trading on Wednesday. The new testing capabilities will include services for LDL cholesterol, lipoprotein(a), and various other cholesterol metrics, significantly broadening the company’s ability to address conditions such as low testosterone and menopausal support.
Additionally, Hims & Hers has incorporated the Tasso+ device into its services. This FDA-cleared blood lancet collects whole blood samples with minimal user intervention. Users can easily attach the device to their upper arm, allowing for convenient blood draws at home.
“Providers on the platform will use the information collected as part of determining a treatment plan for patients,” a company spokesperson explained. Furthermore, de-identified data from the blood work will contribute to the enhancement of artificial intelligence-driven healthcare solutions.
As the telehealth sector continues evolving, Hims & Hers aims to redefine personal healthcare services with its new acquisition and innovative testing options.